Shenqifuzheng injection inhibits lactic acid-induced cisplatin resistance in NSCLC by affecting FBXO22/p53 axis through FOXO3

• Published in: Respiratory research Vol. 25; no. 1; pp. 396 - 15
• Main Authors: Bo, Wei, Wang, Xiaokai, Yu, Ning, Wang, Chun, Liu, Chunying
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.11.2024; BioMed Central; BMC
• Subjects: A549 Cells; Analysis; Animals; Antineoplastic Agents - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Care and treatment; Cisplatin - pharmacology; Cisplatin resistance; Development and progression; Diagnosis; Dosage and administration; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - physiology; Drugs, Chinese Herbal - pharmacology; F-Box Proteins - biosynthesis; F-Box Proteins - genetics; F-Box Proteins - metabolism; FBXO22; Female; Forkhead Box Protein O3 - genetics; Forkhead Box Protein O3 - metabolism; FOXO3; Gene expression; Genetic aspects; Humans; Lactic acid; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Non-small cell lung cancer; p53; Receptors, Cytoplasmic and Nuclear; Shenqifuzheng injection; Tumor suppressor genes; Tumor Suppressor Protein p53 - metabolism; Xenograft Model Antitumor Assays - methods; China; Cisplatin resistance; FOXO3; FBXO22; Shenqifuzheng injection; Non-small cell lung cancer; p53

Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers. Cisplatin (DDP)-based combination chemotherapy is the main treatment of NSCLC. Due to resistance to DDP, 5-year overall survival rate of NSCLC patients is very low. Shenqifuzheng injection (SQFZ) is essential for lung cancer progre...